| Human ANXA2 Protein (LTP10364) |
| LTP10364 |
| 100ug |
|
$406 In stock |
| ANXA2, highly expressed in invasive breast cancer cells, is closely related with poor prognosis, and acts as a molecular switch to EGFR activation. ANXA2 expression is inversely correlated with cell sensitivity to gefitinib. Knockdown of ANXA2 expression in MDA-MB-231 cells increased the gefitinib induced cell death. When ANXA2 was overexpressed in MCF7 cells, the gefitinib induced cell death was decreased. Furthermore, the phosphorylation of ANXA2 at Tyr23 is negatively correlated with the sensitivity of TNBC to gefitinib. |
| Recombinant Human ANXA2 Protein is expressed from E.coli with His tag at the N-terminal. It contains Ser2-Asp339. |
| ANXA2 |
| Human |
| P07355 |
| Ser2-Asp339 |
| The protein has a predicted MW of 39.6 kDa same as Tris-Bis PAGE result. |
| 0 |
| N-His |
| E.coli |
| > 95% as determined by Tris-Bis PAGE |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| ![Human ANXA2 Protein (LTP10364)](/peptide-product/images/protein-products/LTP10364/20210810132217.png) |